Hanyu Pharmaceutical adheres to the core values of "Benevolence is medicine", firmly establishes the consciousness of "the first person responsible for drug quality", abides by national laws, regulations and policies such as the Drug Administration Law, and breaks through the technical bottleneck of large-scale production of polypeptide drugs by introducing digestion and independent innovation on the basis of production management and quality control in strict accordance with GMP. The company has applied for more than 60 invention patents, and has nearly 20 invention patents, 7 national new drug certificates, 5 new drug clinical trial approvals and 46 drug registration approvals. Drugs are mainly used for the treatment of digestive tract, cardiovascular and cerebrovascular diseases, diabetes, infectious diseases, tumors and senile diseases. The company has successively undertaken the national "863 Plan", the national "Tenth Five-Year Plan", "Eleventh Five-Year Plan" and "Twelfth Five-Year Plan" major scientific and technological projects, the national torch plan and the national "major new drug creation", as well as more than 20 major scientific and technological key projects such as major scientific and technological breakthroughs in Guangdong Province, Industry-University-Research and key fields. Participate in the formulation of the national polypeptide drug industry registration standard and the new version of the national pharmacopoeia standard16; Won the "Shenzhen Science and Technology Innovation Award" for four consecutive years, and won the "Shenzhen Key Independent Innovation Product", "Guangdong Science and Technology Second Prize" and "Guangdong Science and Technology Third Prize" 1 item respectively. In 2008, it was awarded the title of "Leading Enterprise of Independent Innovation Industry in Shenzhen" by Shenzhen Municipal People's Government; In 2009, it was recognized as a "national high-tech enterprise"; 20 10 was awarded the title of "national high-tech new peptide drug industrialization demonstration project" by the national development and reform commission; Approved by China Securities Regulatory Commission on 20 1 1, Hanyu Pharmaceutical was first publicly issued and listed on the Growth Enterprise Market, becoming the first synthetic peptide.
In recent years, the company's sales revenue, profits and taxes and other business indicators have increased rapidly. In 2007, the company was selected as one of the "Top 0/00 Most Growing Sci-tech Enterprises in China". In 2008, it was named "Top 50 High-tech and High-growth Enterprises of Deloitte China". In 2009, it was selected as "Zero2IPO-Top 50 Enterprises with the Most Investment Value" and "100 Entrepreneurship State". 20 10 was selected as "Top 200 Potential Enterprises in China" by Forbes magazine, ranking 59th. On 20 1 1 year, the "Guangdong Polypeptide Drug Engineering Technology Research and Development Center" established by the company was recognized as "National Local Joint Engineering Laboratory" by the National Development and Reform Commission. Hanyu Pharmaceutical has a group of technical talents who have returned from studying in the United States, Canada, Britain and other countries, and the personnel engaged in the research and development of polypeptide drugs account for nearly 30% of the total number of employees. With the approval of Guangdong Science and Technology Department, there are two resident science and technology commissioners engaged in school-enterprise cooperation projects in Industry-University-Research. In addition, we have established close cooperative relations with many scientific research institutes at home and abroad, and hired a group of well-known experts as technical consultants of the company. Hanyu Pharmaceutical Co., Ltd. is one of the enterprises with the largest variety of drugs in China Chemical synthetic peptides. Its main products, desmopressin acetate injection, thymopentin for injection, somatostatin for injection and terlipressin for injection, are among the best in the domestic market share, among which terlipressin was also selected as one of the "Top Ten Prescription Drugs in China in 2009" in the National Drug Fair of Sinopharm Lizhan. Internationally, many large-scale distribution enterprises in the United States, Canada, Italy, India, Germany, Russia and other countries have become agents of Hanyu pharmaceutical products in the international market. The national high-tech industrialized polypeptide drug production base under construction is located in the national biomedical base in Pingshan New District, Shenzhen. Fully referring to the cGMP standard in Europe and America, it was identified by the Shenzhen Municipal Party Committee and Municipal Government as one of the 60 landmark major construction projects reflecting the new path of Shenzhen's future urban development and the new direction of industrial transformation and upgrading during the Twelfth Five-Year Plan period.